![Lufax Holding Ltd. [LU] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/LU_e1de3937a8.png)
Lufax Holding Ltd. (LU) faces a class action alleging it misled investors about its financial performance and risk management practices, leading to potential investor losses.
Learn about securities lawsuits tied to your portfolio and recover money!
Lufax Holding Ltd. (NYSE: LU) is facing a securities class action after investors alleged the company misstated the effectiveness of its internal controls and materially misstated portions of its 2022 and 2023 financial results. The complaint centers on repeated assurances in the company’s 2022 and 2023 Form 20-F filings that disclosure controls and internal control over financial reporting were effective, statements investors now allege were false when made.
The alleged truth began to surface on January 27, 2025, when Lufax disclosed that PricewaterhouseCoopers had raised serious concerns involving possible related-party transactions, refused to allow reliance on its prior 2022 and 2023 audit opinions, and signaled that the company’s previously issued annual reports should no longer be trusted. What followed was the kind of causal chain securities litigators know well: accounting concerns, audit repudiation, delayed reporting, and a sharp multi-day selloff in LU ADSs.
For investors, the case reads as a classic internal-controls and financial-restatement securities fraud action under Sections 10(b) and 20(a) of the Exchange Act, with allegations focused on scienter, market inflation, and loss causation.
“Most LU shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Lufax describes itself as a leading financial services enabler for small business owners in China, operating through ADSs listed on the NYSE under the ticker LU. The complaint identifies CEO Yong Suk Cho and former CFO David Siu Kam Choy as the principal executive defendants.
The business context matters because the alleged misconduct was not framed around a single failed product or isolated operational miss. Instead, investors allege the company’s public reporting architecture itself was compromised. In both the 2022 and 2023 Annual Reports, management represented that disclosure controls and internal control over financial reporting were effective under the COSO framework.
That matters in a financial platform business where reported income quality is inseparable from investor trust. When the integrity of reported line items becomes suspect, valuation compression can be swift.
The complaint draws a direct contrast between Lufax’s repeated internal-controls assurances and what later emerged through auditor conflict and re-audit findings. In April 2023, Lufax told investors its disclosure controls were “effective” and that internal control over financial reporting was effective as of December 31, 2022. The same assurances were repeated in the 2023 Annual Report filed in April 2024.
Investors now allege those assurances concealed deficient controls and misstated profitability. The complaint specifically alleges Lufax materially overstated net profit for both 2022 and 2023. The later 2024 Form 20-F, filed after the class period, gave the allegations numerical weight. According to the complaint, the company disclosed that re-audited results reduced net profit by approximately RMB917.0 million for 2022 and RMB81.4 million for 2023.
This is where the narrative hardens from allegation into claimed loss causation: management said controls worked; the auditor later said prior opinions could no longer be relied upon; the company then restated earnings downward.
The alleged class period runs from April 7, 2023 through January 26, 2025.
First came the 2022 and 2023 annual filings, where Lufax repeatedly certified control effectiveness and reported profits later alleged to be misstated.
Then came the fracture point: on January 27, 2025, the company disclosed PwC’s concerns regarding possible related-party transactions, questions surrounding the independence of the audit committee investigation, and PwC’s position that its 2022 and 2023 audit opinions should no longer be relied upon.
The market reaction was immediate and cumulative:
Finally, on February 17, 2026, Lufax filed its 2024 Annual Report and disclosed the re-audit and restated figures.
The complaint ties investor harm directly to the three-day collapse that followed the auditor-related disclosure. The total multi-session decline took LU ADSs from $2.89 implied pre-disclosure levels to $2.26, a drop of roughly 21.8% across three trading days based on the complaint’s stated closing prices.
Loss causation is alleged through the market’s repricing once investors learned two critical facts: first, prior audited reports could not be relied upon, and second, the company faced delays in reporting its 2024 annual results.
The economic harm theory is straightforward: LU traded at artificially inflated levels while investors relied on misstated profitability and control assurances, then repriced downward once reliability itself collapsed.
The case is pending in the U.S. District Court for the Central District of California as Mau v. Lufax Holding Ltd., et al., Case No. 2:26-cv-03071. The complaint asserts: Section 10(b) and Rule 10b-5 claims against all defendants, and Section 20(a) control-person claims against the CEO and former CFO.
Scienter allegations focus on the senior officers’ roles in signing SOX certifications, overseeing internal controls, and allegedly knowing the true state of the company’s financial reporting. The complaint seeks class certification for all purchasers of Lufax ADSs during the class period and damages tied to the post-disclosure decline.
Retail commentary visible on public investor forums appeared mixed but notably cautious after Lufax’s auditor-related disclosure. Forum posts on LU reflected frustration over the stock’s continued decline, while some users still framed the shares as oversold or a speculative recovery play. Taken together, that public retail reaction was directionally consistent with the company’s January 27, 2025 announcement that it was proposing to remove PwC, warning of possible reporting delays, and disclosing that the 2022 and 2023 audit opinions should no longer be relied upon.
Before the January 27, 2025 disclosure, published analyst commentary was already cautious rather than strongly bullish. MarketScreener’s analyst summary shows Morgan Stanley trimming its price target on January 2, 2024 while maintaining Equal-Weight, Citigroup adjusting its target to $5.10 on April 23, 2024 while maintaining Neutral, and Jefferies downgrading LU to Hold on October 24, 2024 with a $3.20 target. That record supports describing pre-disclosure analyst sentiment as measured and guarded, not enthusiastic.
After the disclosure, commentary became more tied to governance and reporting-credibility risk. Lufax’s filing disclosed the proposed auditor removal and the non-reliance on prior audit opinions, while later commentary continued to frame the stock through a high-risk value or rebound lens rather than a clean recovery narrative. A concise and supportable takeaway is that post-disclosure commentary focused less on upside catalysts and more on whether LU’s discounted valuation reflected opportunity or justified skepticism.
The SEC filing trail is central to this lawsuit. The allegedly misleading statements stem from the April 7, 2023 Form 20-F and the April 23, 2024 Form 20-F, each of which represented effective internal controls and disclosed profits now alleged to have been materially misstated.
The corrective disclosure arrived through a January 27, 2025 Form 6-K, which attached the company’s announcement regarding PwC’s concerns and the loss of reliance on prior audits. The post-class-period confirmation came in the February 17, 2026 Form 20-F, where Lufax disclosed the re-audit findings and restated net-profit declines.
The omitted risk alleged here is not abstract macro risk. It is the failure to disclose that historical profits and internal controls were materially unreliable.
The Lufax securities class action is, at its core, a case about what happens when the reliability of audited financial history itself becomes the corrective disclosure. The red flag for investors is not merely a restatement. It is the sequence: auditor alarm, non-reliance language, delayed reporting, and then a re-audit that materially cuts prior profits. That chain often becomes the backbone of scienter and loss-causation arguments in Rule 10b-5 litigation.
For investors evaluating foreign-listed financial platforms, the case underscores a familiar lesson: governance and control disclosures can matter as much as revenue growth. Sometimes more.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
![Gartner, Inc. [IT] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/IT_c9924f05d0.png)
Gartner, Inc. (IT) faces a class action alleging it misled investors about contract value growth and consulting performance. The lawsuit claims the company concealed slowing demand, leading to losses after disclosures triggered significant stock declines.
![Trip.com Group Limited [TCOM] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/TCOM_d0b18dde74.png)
Trip.com Group Limited (TCOM) faces a class action alleging it misled investors by understating antitrust regulatory risks in China. The lawsuit claims the company framed active regulatory scrutiny as hypothetical, leading to investor losses after news of a probe triggered a sharp stock decline.
![Gemini Space Station, Inc. [GEMI] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/GEMI_cfc826b1af.png)
Gemini Space Station, Inc. (GEMI) faces a class action alleging it misled investors about its growth strategy and international expansion. The lawsuit claims the company failed to disclose restructuring risks, leading to losses after a strategic pivot and executive departures triggered a sharp stock decline.